key: cord-0775888-2una9767
authors: Guo, Lu; Sun, Xuehan; Wang, Xinge; Liang, Chen; Jiang, Haiping; Gao, Qingqin; Dai, Moyu; Qu, Bin; Fang, Sen; Mao, Yihuan; Chen, Yangcan; Feng, Guihai; Gu, Qi; Wang, Liu; Wang, Ruiqi Rachel; Zhou, Qi; Li, Wei
title: SARS-CoV-2 detection with CRISPR diagnostics
date: 2020-04-11
journal: bioRxiv
DOI: 10.1101/2020.04.10.023358
sha: cdf2bb810fd33f983b42c461eabae8e4472ec434
doc_id: 775888
cord_uid: 2una9767

The novel coronavirus (CoV) disease termed COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) is causing a massive pandemic worldwide, threatening public health systems across the globe. During this ongoing COVID-19 outbreak, nucleic acid detection has played an important role in early diagnosis. Here we report a SARS-CoV-2 detection protocol using a CRISPR-based CRISPR diagnostic platform - CDetection (Cas12b-mediated DNA detection). By combining sample treatment protocols and nucleic acid amplification methods with CDetection, we have established an integrated viral nucleic acid detection platform - CASdetec (CRISPR-assisted detection). The detection limit of CASdetec for SARS-CoV-2 pseudovirus is 1 × 104 copies/mL, with no cross reactivity observed. Our assay design and optimization process can provide guidance for future CRISPR-based nucleic acid detection assay development and optimization.

The novel coronavirus (CoV) disease termed caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) is causing a massive pandemic worldwide, threatening public health systems across the globe. During this ongoing COVID-19 outbreak, nucleic acid detection has played an important role in early diagnosis. Here we report a SARS-CoV-2 detection protocol using a CRISPR-based CRISPR diagnostic platform -CDetection (Cas12b-mediated DNA detection). By combining sample treatment protocols and nucleic acid amplification methods with CDetection, we have established an integrated viral nucleic acid detection platform -CASdetec (CRISPR-assisted detection). The detection limit of CASdetec for SARS-CoV-2 pseudovirus is 1 × 10 4 copies/mL, with no cross reactivity observed. Our assay design and optimization process can provide guidance for future CRISPR-based nucleic acid detection assay development and optimization.

The novel coronavirus (CoV) disease termed caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) [1] is causing a massive pandemic worldwide, threatening public health systems across the globe. During this ongoing COVID-19 outbreak, nucleic acid detection has played an important role in early diagnosis [2] . To date, 4 protocols based on CRISPR for detecting SARS-CoV-2 have been published [3] [4] [5] [6] . Using lateral flow protocols, RNA samples harboring more than 1 × 10 4 -1 × 10 5 copies/mL (SHERLOCK) or 1 × 10 4 copies/mL (DETECTR) can be detected within 1 hour. In addition to these reported efforts, we have also established a SARS-CoV-2 detection protocol based on our previously reported platform -CDetection (Cas12b-mediated DNA detection) [7] . By combining sample treatment protocols and nucleic acid amplification methods with CDetection, we have established an integrated viral nucleic acid detection platform -CASdetec (CRISPR-assisted detection). The detection limit of CASdetec for SARS-CoV-2 pseudovirus is 1 × 10 4 copies/mL, with no cross reactivity observed. Here we present our assay design and optimization process, which could provide guidance for future CRISPR-based nucleic acid detection assay development and optimization.

To optimize the output of fluorescence signal, we designed and synthesized poly-T fluorescence-quenchers of varying nucleotide lengths, namely 4 nt, 5 nt, 7 nt, 12 nt, 17 nt, 22 nt and 27 nt. Of all the lengths tried, the 7 nt poly-T reporter provided the highest signals in the shortest amount of time (Supplementary information, Fig. S1a, b) . Based on this observation, we applied the 7 nt poly-T reporter in later experiments.

According to the published SARS-CoV-2 whole genome sequence [8] , we designed 7 sgRNAs around the RdRp locus, as recommended by the World Health Organization (WHO) [2] (Supplementary information, Fig. S2a ). Due to its high similarity to SARS-CoV, we ran initial experiments on both SARS-CoV-2 and SARS-CoV plasmids. According to fluorescence kinetics studies, sgRNA-3 stood out in not only being able to distinguish between the 2 similar coronaviruses but also being able to produce the most distinct As previously demonstrated, CRISPR is unable to detect any target DNA when there is less than 1-10 nM of amplification product within the reaction mix [7] . Hence, increasing the molecular collisions between CRISPR and target would be essential to improve sensitivity.

We found out that increasing the sgRNA concentration by 3 folds not only enhances the fluorescence signal and the signal-to-background ratio, but also increases the rate of reaction Given that the average viral load in the plasma of SARS patients ranged from less than 1 to about 1000 copies per microliter [9] , or 1 × 10 3 -1 × 10 6 copies/mL, nucleic acid amplification techniques are needed to produce sufficient DNA for CRISPR-based DNA detection methods. Recombinase-aided amplification (RAA) can amplify substrates 10 10 times at most (from aM to 10 nM) within 10-30 minutes at constant temperature between 37 o C to 42 o C, complementing the needs of CRISPR-based detection. Thus, we designed and screened RAA primers that matched our previously optimized sgRNA-3 (Supplementary information, Fig. S4a ). Based on our screens, we found that by using the best primer pairs together with sgRNA-3, we can detect SARS-CoV-2 RNA in samples containing 5 × 10 3 copies/mL ( Fig. 1c and Supplementary information, Fig. S4b-c) .

In addition, we aligned the selected primers and sgRNAs to the existing typical coronavirus sequences to evaluate their specificity. We analyzed all SARS-CoV-2 sequences The experiments above were conducted by executing RT-RAA nucleic acid amplification and CDetection separately. However, it would be best to conduct both reactions within a single tube for convenience and, more importantly, to prevent aerosol contamination which happens when the reaction mixture has to be exposed to the environment midway through the protocol. Hence, we tried to execute both the RT-RAA and CDetection concurrently within a single tube. However, the combination resulted in a drastic decrease in sensitivity ( Fig. 1c and Supplementary information, Fig. S7 ). Therefore, in order to keep both the RT-RAA and CRISPR reactions within a single tube, we executed the RT-RAA reaction within the tube while keeping the CDetection reagents within the lid of the tube for 30 minutes, following which, the CDetection reagents were spun down into the tube for nucleic acid detection, and the resultant reaction mixture was imaged for fluorescence.

To validate the specificity of our method for SARS-CoV-2 nucleic acid detection, we tested our protocols against 6 coronaviruses known to cause respiratory diseases (SARS-CoV, MERS-CoV, CoV-HKU1, CoV-229E, CoV-OC43 and CoV-NL63). Consistent with alignment analysis (Supplementary information, Fig. S6a-c) , no cross-reactivity with other endemic human coronavirus were detected (Fig. 1d) . Our results suggested our set of sgRNA and primers showed high sensitivity and specificity.

However, viral genomes are packaged inside capsid protein and need to be released.

Thus, to investigate the virus handling processes, we produced pseudoviruses by packaging the target sequences of SARS-CoV-2, SARS-CoV, MERS-CoV into actual lentivirus particles (Supplementary information, Fig. S8 ). These pseudoviruses were diluted serially and treated with either virus genome extraction kits (spin column) or lysis buffer, respectively. Our results demonstrated that the spin column treatment gave a lower detection limit of 1 × 10 4 copies/mL (Fig. 1e) . On the other hand, the lysis buffer offered higher usability, but raised the detection limit to 5 × 10 4 copies/mL (Fig. 1f) . Due to the difference in detection limit between spin column and lysis buffer, we suggest using the spin columns in hospitals, and using the lysis buffer for point-of-care testing (POCT).

To make CASdetec more amenable for POCT, we have also constructed a portable dark box containing a blue LED and demonstrated that the positive fluorescence signal generated from the protocol can be visualized upon illumination by a blue LED (Fig. 1g) . In conclusion, we have established a CRISPR-assisted detection (CASdetec) platform which consists of procedures including virus handling, nucleic acid amplification and CRISPR-based detection (Fig. 1h) . CASdetec can detect pseudovirus samples with more than 1 × 10 4 copies/mL, with no cross-reactivity with other endemic human coronaviruses. In addition, we optimized the workflow to run both reactions within one single tube without lid opening. This will thus prevent aerosol contamination and reduce the false positive rate.

We thank Prof. Ng Shyh Chang from Institute of Zoology, CAS for his critical support 

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

A protocol for detection of COVID-19 using CRISPR diagnostics

CRISPR-based COVID-19 surveillance using a genomically-comprehensive machine learning approach

An ultrasensitive, rapid, and portable coronavirus SARS-CoV-2 sequence detection method based on CRISPR-Cas12

Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay

CDetection: CRISPR-Cas12b-based DNA detection with sub-attomolar sensitivity and single-base specificity

Novel 2019 coronavirus genome

Detection of SARS coronavirus in plasma by real-time RT-PCR